XBiotech Reports Material Agreement, Officer/Director Changes
Ticker: XBIT · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1626878
| Field | Detail |
|---|---|
| Company | Xbiotech Inc. (XBIT) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1,250,000, $4,530,442 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, management-change, corporate-governance
Related Tickers: XBI
TL;DR
XBiotech's 8-K: New deals, exec shake-up, director changes. Big moves happening.
AI Summary
XBiotech Inc. filed an 8-K on October 3, 2025, reporting on events that occurred on October 1, 2025. The filing indicates an entry into a material definitive agreement, the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. The company is incorporated in British Columbia, Canada, and its principal executive offices are located in Austin, TX.
Why It Matters
This 8-K filing signals significant corporate governance and strategic shifts within XBiotech Inc., potentially impacting its operational direction and leadership structure.
Risk Assessment
Risk Level: medium — Changes in directors, officers, and material agreements can indicate significant strategic shifts or internal restructuring, which carry inherent business risks.
Key Players & Entities
- XBiotech Inc. (company) — Registrant
- October 1, 2025 (date) — Earliest event reported
- October 3, 2025 (date) — Filing date
- British Columbia, Canada (location) — State of Incorporation
- Austin, TX (location) — Principal executive offices
FAQ
What specific material definitive agreement did XBiotech Inc. enter into?
The filing does not specify the details of the material definitive agreement, only that one was entered into on October 1, 2025.
Who are the directors or officers that have departed from XBiotech Inc.?
The filing indicates departures but does not name the specific individuals involved.
Who has been elected as new directors or appointed as new officers at XBiotech Inc.?
The filing mentions the election of directors and appointment of officers but does not provide their names.
What are the details of the compensatory arrangements for the officers mentioned?
The filing notes that compensatory arrangements are part of the report, but specific details are not provided in this summary.
What is the significance of the filing date being October 3, 2025, for events on October 1, 2025?
The filing date of October 3, 2025, indicates that the report is being filed promptly after the earliest event reported on October 1, 2025, as required by SEC regulations.
Filing Stats: 792 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2025-10-03 11:15:44
Key Financial Figures
- $1,250,000 — n his current annual Base Salary of USD $1,250,000. Mr. Simard will also be eligible to re
- $4,530,442 — to receive an annual Base Bonus of USD $4,530,442.00, which reflects the average annual b
Filing Documents
- f8k_100325.htm (8-K) — 22KB
- exh_101.htm (EX-10.1) — 49KB
- 0001171843-25-006266.txt ( ) — 237KB
- xbio-20251001.xsd (EX-101.SCH) — 3KB
- xbio-20251001_lab.xml (EX-101.LAB) — 33KB
- xbio-20251001_pre.xml (EX-101.PRE) — 22KB
- f8k_100325_htm.xml (XML) — 3KB
01 Entry into a Definitive Material Agreement
Item 1.01 Entry into a Definitive Material Agreement.
02 Departure of Directors or Certain Officers; Election of Directors; Appointment
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 2, 2025, John Simard and XBiotech, Inc. (the "Company") entered into an Executive Employment Agreement (the "Agreement"), with an effective date of October 1, 2025, to replace and supersede all prior employment agreements between Mr. Simard and the Company. The Agreement was approved by the Company's Compensation Committee formed of Independent Directors. The Agreement formalizes Mr. Simard's compensation trends over the past five years and recognizes Mr. Simard's past and ongoing contributions to the Company, the importance of his continued leadership, and the need to facilitate transition in the event of Mr. Simard's departure or retirement. Under the Agreement, Mr. Simard will maintain his current annual Base Salary of USD $1,250,000. Mr. Simard will also be eligible to receive an annual Base Bonus of USD $4,530,442.00, which reflects the average annual bonus paid over the past 5 years, but which will be determined each calendar year by the Compensation Committee. The amount of the Base Salary and Base Bonus shall be adjusted for inflation at the end of each calendar year as provided in the Agreement. The Compensation Committee shall also have discretion to award Mr. Simard stock options and additional cash bonus amounts if the Compensation Committee determines such options or amounts are warranted. Mr. Simard will also be entitled to reimbursement of reasonable and documented expenses and to participate in the Company's benefit programs. The Agreement also provides that in the event of Mr. Simard's retirement, departure due to Disability, or termination without Cause (with the terms "Disability" and "Cause" having the meanings as defined in the Agreement), Mr. Simard or his estate shall receive a severance payment equal to three (3) full calendar years of Base Salary and three (3) full calen
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description of Exhibit 10.1 Executive Employment Agreement for John Simard 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 3, 2025 XBIOTECH INC. By: /s/John Simard John Simard Chief Executive Officer and President